CD274 and prostate cancer: GBM has a higher frequency of PD-L1 expression (30%–70%) than that of other solid tumors [52–55], such as melanoma, non-small cell lung cancer, prostate cancer and rectal cancer, suggesting that PD-L1 plays a strategic role in immunosuppression in various GBM molecular subtypes.